Expression of inhibitor of differentiation-1 gene in bone marrow mononuclear cells of patients with acute myeloid leukemia
YAO Xin-yu1,2, ZHOU Jing-dong1,2, ZHANG Ting-juan1,2, LIN Jiang3, ZHANG Wei1, QIAN Jun1
(1. Department of Hematology, the Affiliated People′s Hospital of Jiangsu University, Zhenjiang Jiangsu 212002; 2. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 3. Laboratory Center, the Affiliated People′s Hospital of Jiangsu University, Zhenjiang Jiangsu 212002, China)
Abstract：Objective: To explore the expression of inhibitor of differentiation1(ID1) gene in bone marrow mononuclear cells and its clinical significance in patient with acute myeloid leukemia(AML). Methods: Realtime quantitative PCR was applied to detect ID1 transcript level in bone marrow mononuclear cells from 153 de novo AML patients. Results: ID1 transcript level in AML patients ranged from 0.000 to 3.536(median 0.030). According to the median level of ID1 expression, AML patients were divided into two groups, i.e. high ID1 expression and low ID1 expression. No significant differences were found in sex, peripheral platelet, and common gene mutations between two groups(P>0.05). There were tendency towards the differences between two groups in peripheral white blood cell, peripheral hemoglobin, FAB subtypes, WHO classifications, karyotypes, and karyotypic risks(P<0.10). However, significant differences were observed in age and percentage of bone marrow blasts between two groups(P<0.05), and high ID1 expression was associated with older age(P=0.033) and higher percentage of bone marrow blasts (P=0.035). Patients with high ID1 expression presented a significantly lower complete remission(CR) rate than those with low ID1 expression(P<0.01), and AML patients who can achieve CR in 12 course of induction chemotherapy showed a significantly lower ID1 expression in newly diagnosis time than those who cannot achieve CR in 12 course of induction chemotherapy(P=0.001). Survival analysis showed that patients with high ID1 expression had a shorter overall survival(OS) than those with low ID1 expression in whole AML, nonM3 AML, and cytogenetically normal AML(P=0.002, 0.008, and 0.050, respectively). Conclusion: The level of ID1 expression may act as a potential biomarker associated with chemotherapy response and prognosis in AML.
［1］Estey E, Dhner H. Acute myeloid leukemia\[J\]. Lancet, 2006,368(9550):1894-1907.［2］Grimwade D, Mrózek K. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia\[J\]. Hematol Oncol Clin North Am, 2011,25(6):1135-1161.［3］Mrzek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and geneexpression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?\[J\]. Blood, 2007, 109(2):431-448.［4］Lasorella A, Benezra R, Iavarone A. The ID proteins: master regulators of cancer stem cells and tumour aggressiveness\[J\]. Nat Rev Cancer, 2014, 14(2):77-91.［5］Tang R, Hirsch P, Fava F, et al. High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia\[J\]. Blood, 2009, 114(14):2993-3000.［6］Damm F, Wagner K, G rlich K, et al. ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukemia\[J\]. Br J Haematol, 2012, 158(2):208-215.［7］Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the FrenchAmericanBritish Cooperative Group\[J\]. Ann Intern Med, 1985,103(4):620-625.［8］Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes\[J\]. Blood, 2009,114(5):937-951.［9］Zhou JD, Zhang TJ, Li XX, et al. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies\[J\]. J Cell Mol Med, 2017,21(8):1468-1481.［10］杨海燕,周静东,杨磊,等.急性髓系白血病患者BAALC的表达及其临床意义\[J\].江苏大学学报(医学版), 2015, 25(2):169-174.［11］Wen XM, Lin J, Yang J, et al. Double CEBPA mutations are prognostically favorable in nonM3 acute myeloid leukemia patients with wildtype NPM1 and FLT3ITD\[J\]. Int J Clin Exp Pathol, 2014, 7(10):6832-6840.［12］Lin J, Yao DM, Qian J, et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome\[J\]. PLoS One, 2011,6(10):e26906.［13］Lin J, Yao DM, Qian J, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome\[J\]. Ann Hematol, 2012,91(4):519-525.［14］Su L, Li X, Gao SJ, et al. Cytogenetic and genetic mutation features of de novo acute myeloid leukemia in elderly Chinese patients\[J\]. Asian Pac J Cancer Prev, 2014, 15(2):895-898.［15］Nigten J, Breemsde Ridder MC, ErpelinckVerschueren CA, et al. ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells\[J\]. Leukemia, 2005,19(5):799-805.［16］Suh HC, Leeanansaksiri W, Ji M, et al. Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo\[J\]. Oncogene, 2008, 27(42):5612-5623.
2018, Vol. 28 
